RealTime Dynamix™: Hyperkalemia US Q1 2019 Spotlight
RealTime Dynamix™: Hyperkalemia US Q1 2019 Spotlight https://www.spherixglobalinsights.com/wp-content/uploads/2019/06/RTD-HK-Q1-2019.pngDownload Report Spotlight Last week the FDA approved two products, Pfizer’s Retacrit and AstraZeneca’s Lokelma, both of which encountered lengthy regulatory delays. Retacrit is the first biosimilar ESA to enter the US market and will compete with Amgen’s Epogen and Aranesp and Roche’s Mircera. Lokelma (sodium zirconium cyclosilicate) […]
Spherix Global Insights’ Recent Multiple Sclerosis Chart Audit Shows That the Current First-Line Opportunity for High-Efficacy Disease-Modifying Therapies, Including Genentech’s Ocrevus and Biogen’s Tysabri, May Be Limited By A Small Unfavorable Prognosis Segment Size
Conversely, new start shares for Teva’s Copaxone, Biogen’s Tecfidera, Genzyme’s Aubagio, and EMD Serono’s Rebif are buoyed by preferential prescribing among the high volume of patients presenting with a favorable long-term prognosis at the time of therapy initiation Download Report Overview EXTON, Pa., February 12, 2019 ―With increasing focus on the early implementation of high-efficacy […]
Spherix Global Insights’ Quarterly Update on the US Migraine Prevention Market Confirms the Value of First-to-Market Status for Amgen and Novartis’ Aimovig as Teva’s Ajovy and Eli Lilly’s Emgality Strive to Differentiate From the Class Leader and Each Other
With insurance coverage and patient cost frequent barriers to greater anti-CGRP brand uptake irrespective of the availability of free drug voucher programs, topiramate and Allergan’s Botox continue to be US neurologists and migraine/headache specialists’ most preferred and most prescribed migraine preventive therapies, according to a new report from Spherix Global Insights Download Report Overview EXTON, […]
Recent Data Collected by Spherix Global Insights Highlights Key US vs. EU Differences Between Perceptions and Adoption of Eli Lilly’s Olumiant and Pfizer’s Xeljanz for the Treatment of Rheumatoid Arthritis
Despite the introduction of Olumiant to the US market in June of 2018, Xeljanz has been able to maintain preference among stateside rheumatologists; however, in the EU, where Olumiant secured the first-to-market position, the story is quite different. EXTON, Pa., January 16, 2019 /PRNewswire/ — Analysis of Spherix Global Insights’ RealTime Dynamix™: Rheumatoid Arthritis market tracker […]
Janssen’s Stelara and Pfizer’s Xeljanz Battle Takeda’s Entyvio to Claim the Preferred Alternate Mechanism of Action Position in Inflammatory Bowel Disease Patients Who Are Being Switched from Their Current Treatment
The practice of TNF inhibitor cycling is on the decline, according to Spherix Global Insights. These findings are based on a large-scale patient chart review of over 1,000 patients with Crohn’s disease or ulcerative colitis who recently switched biologic or JAK inhibitor therapy. EXTON, Pa., Jan. 14, 2019 /PRNewswire/ — Spherix Global Insights published the […]
Spherix Global Insights’ Quarterly Update on the Multiple Sclerosis Market Reveals a Unique Role for Genzyme’s Aubagio As the Only Oral Standard-Efficacy Therapy for First-Line Treatment of Relapsing-Remitting Multiple Sclerosis
Currently positioned by US neurologists to compete with Novartis’ siponimod in the later-line secondary progressive multiple sclerosis patient segment, EMD Serono’s Mavenclad could compete most successfully by strategically positioning the brand for first-line use in highly active relapsing multiple sclerosis patients, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., […]
In Rheumatoid Arthritis, TNF Cycling Continues to Be Highly Prevalent, Though Alternate Mechanism Agents Are Capturing a Greater Percentage of the Switching Population Compared to the Prior Year
According to the latest patient audit analysis from Spherix Global Insights, biosimilars have gained ground, but the overall infliximab pie in the rheumatoid arthritis switching segment is beginning to shrink Download Report Overview Exton, PA., December 4, 2018 /PRNewswire/ — In Spherix Global Insight’s third annual RealWorld Dynamix: Biologic/JAK Switching in Rheumatoid Arthritis (US) study, […]
Spherix Global Insights’ Annual Update of the Psoriasis Switching Market Reveals Significant Gains for Janssen’s Tremfya, Much to the Detriment of Sister-Brand Stelara
US dermatologists are keen on moving to a biologic with an alternative mechanism of action in the second- or later-line setting, with Tremfya claiming the title as biggest winner of the 2018 switching game Download Report Overview Exton, PA., November 20, 2018 / PRNewswire / — Biologic agents with alternate mechanisms of action (MOA) for […]
Recent Progressive Forms of Multiple Sclerosis Chart Audit Provides Evidence That the Institute for Clinical and Economic Review’s Comparators of Interest for Novartis’ Siponimod Assessment May Not Be Relevant for the Not Active Secondary Progressive Multiple Sclerosis Segment
While Roche’s Ocrevus dominates the primary progressive multiple sclerosis segment, neurologists’ perceptions of the brand drive some to prescribe alternative monoclonal antibody therapies, according to a recently published independent audit from Spherix Global Insights Download Report Overview EXTON, Pa., Nov. 13, 2018 /PRNewswire/ — The Institute for Clinical and Economic Review (ICER) released their draft background and scope document on October […]
Sanofi/Regeneron’s Dupixent Continues to Flourish as the Only Atopic Dermatitis Game in Town, but US Dermatologists Identify a Gap Between Current Patients and Candidates for Treatment
With Dupixent only capturing a piece of the potential candidate pie, there remains ample runway for new agents in development to enter this highly dynamic market. Download Report Overview EXTON, Pa., Nov. 7, 2018 /PRNewswire/ – After over a year and a half on the market, U.S. dermatologists (n=102) remain extremely pleased with Sanofi/Regeneron’s Dupixent. In Spherix’s fourth quarter […]
